Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Users of Reloxin: Dermatologists(?)

Council Members in this Study Group: 100

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Jeffrey Weinberg
Director of Clinical Research - Dermatology
ST LUKE'S-ROOSEVELT HOSPITAL CENTER

Jeffrey Weinberg, MD, is the Director of the Clinical Research Center in the Department of Dermatology at St. Luke's-Roosevelt Hospital Center and Beth Israel Medical Center in New York. He is also an Assistant Clinical Professor in the Dermatology Department at Columbia University College of Physicians...

Kenneth Edelson
Owner
Kenneth Edelson, MD

Kenneth Edelson, MD, FAACS, is a Dermatologist in private practice in New York, since July 1980. He specializes in skin cancer as well as cosmetic dermatology, including lasers and IPL's for facial rejuvenation and skin tightening, vascular lesions, pigmentation, and cellulite. Dr. Edelson uses lasers...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
wrinkle fillers | 11-24-2008
Analysis of: FDA Faults Wrinkle Fillers Over Warnings | online.wsj.com
Author: GLG Expert Contributor

fillers are important in cosmetic practice but caution must be observed till insurer is ready to compensate for any loss  done.

Intermittent Use of Topical Tacrolimus in Stable Atopic Dermatitis | 07-18-2008
Author: GLG Expert Contributor

Tacrolimus is used either alone or with topical steroids in acute stages while tacrolimus alone is preferred for maintenance so as to reduce the side effects of steroids. Relapses are a rule rather than exception in atopic dermatitis. Use of moisturizing cleansers, emollients and avoidance of irritants...

It's All in the Eyes | 06-23-2008
Analysis of: Putting ‘You Look Tired’ to Rest | www.nytimes.com
Author: GLG Expert Contributor

- Dark circles underneath the eyes give the unappealing impression of exhaustion. Many factors, both hereditary and environmental, can produce or exacerbate this condition.  - Despite efforts to address this unmet need, the over-the-counter cosmetic industry has not been able to address consumer's...

Issues with Ustekinumab | 06-23-2008
Author: Jeffrey Weinberg, Director of Clinical Research - Dermatology, ST LUKE'S-ROOSEVELT HOSPITAL CENTER

On Tuesday, the FDA's Dermatologic and Ophthalmic Drug Advisory Panel voted unanimously to approve the use of the injectable drug for the treatment of plaque psoriasis, a severe skin disease. As the FDA usually follows the recommendations of its advisory panels when reviewing new drugs for approval,...

Ustekinumab Shows Great Promise for the Treatment of Psoriasis | 03-17-2008
Author: GLG Expert Contributor

(Directly pulled from the article.) Patients were randomly assigned to receive 2 doses, 45 or 90 mg, of subcutaneous ustekinumab, given 4 weeks apart and followed by treatments every 12 weeks.  Patients randomly assigned to receive 45 mg had a sustained PASI 75 (indicating an improvement in psoriatic...

View All GLG News by members of this Study Group

GLG InstituteSM Seminars with this Study Group's Leading Experts(?)

 

Recent Seminars

Most Common Company Types:

  • Office Based Private Practice or Clinic
  • Academic Medical Center/Hospital or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Owner
  • Physician - Director
  • Director
  • Physician - Division Head
  • President

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-12-05T01:45:24.617